FDA • Drug Quality • Supply Chain • Pharmacy Operations

FDA’s New Drug-Quality Initiative Includes Retail Pharmacy Samples

FDA announced its Enhanced Approach for Sampling and Testing on November 18. The agency plans to test drug samples from retail pharmacies and wholesale distributors, using modern screening and traditional methods to assess identity, purity, and potency. Results will guide inspection priorities and possible regulatory action. FDA announced no new pharmacy testing requirement or compliance deadline. Chad’s analysis: pharmacies can review how they retrieve supplier and lot information and handle quality complaints.

By Toby C. “Chad” Frost • November 18, 2026
1 min read

What FDA announced

FDA launched its Enhanced Approach for Sampling and Testing, known as EAST, on November 18. The initiative combines modern screening with traditional testing and expands coverage across manufacturers, therapeutic classes, and geographic regions in the United States and abroad.1

The agency will test samples from retail pharmacies and wholesale distributors for identity, purity, and potency. It plans to use the findings to identify quality risks, assess the need for regulatory action, and prioritize future inspections. The announcement builds on existing surveillance and identifies no pharmacy compliance deadline, new pharmacy laboratory-testing requirement, or particular product recall.1

What pharmacies can review

Chad’s analysis: Check whether staff can retrieve supplier, lot, and expiration information for sampled stock and route a quality complaint to the appropriate person. Keeping that information accessible can support a response to an inquiry and later product-level follow-up. These are operational suggestions. The announcement does not establish that a pharmacy’s stock has a quality defect.1

Source notes

  1. U.S. Food & Drug Admin., FDA Introduces New Approach to Drug Quality Sampling and Testing (Nov. 18, 2026).